MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
African Trials Moving Ahead with Great Success
Our vaccine is currently being tested for safety, tolerability and efficacy in Mali (West Africa) and Tanzania (East Africa).
Sanaria’s Dr. Stephen L. Hoffman won the Daily Record’s Innovator of the Year Award
Check out more from the Innovator of the Year awards.
In memoriam: Donald ‘DA’ Henderson
Sanaria joins the international public health community in remembering Donald 'DA' Henderson after his death on August 19, 2016. Sanaria was honored to receive a visit from DA in June 2011, where after describing his relentless dedication to the eradication of Smallpox, he offered insights, advice and encouragement to Sanaria at what was a critical time in our PfSPZ Vaccine clinical development program.
Weill Cornell Alumni Association Honors Dr. Stephen Hoffman
This year, Dr. Stephen Hoffman, M.D. ’75 was awarded the Weill Cornell Medicine Alumni Association Award of Distinction for his significant accomplishments as a physician, scientist and entrepreneur. Watch:
Could This Be the First Malaria Vaccine?
US News & World Report features a story on Sanaria's new finding that our experimental vaccine against malaria has provided protection for some against the illness for more than a year.
Sanaria’s Malaria Vaccine Yields Unprecedented Protection In Clinical Trial
Results of a clinical trial of Sanaria® PfSPZ (Plasmodium falciparum sporozoite) Vaccine to prevent malaria infections, published today in the online issue of Nature Medicine magazine, show that the vaccine provided protection against infection with malaria parasites for at least 14 months in subjects who were exposed to Plasmodium falciparum parasites. The findings put the Sanaria vaccine on track to be the first malaria vaccine providing durable protection against infection with malaria parasites. Plasmodium falciparum is the malaria parasite that causes about 438,000 deaths and 214 million cases annually.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.